Navigation Links
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
Date:7/28/2008

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary results of a Phase II study of intravenous (i.v.) peramivir administered via a single dose injection in the outpatient setting for the treatment of seasonal influenza. The trial, conducted by BioCryst's partner, Shionogi & Co., Ltd. in Japan, met its primary endpoint of improvement in the median time to alleviation of symptoms in subjects with confirmed, acute, uncomplicated influenza infection, compared to placebo alone. This result was highly statistically significant. Further, safety assessments confirmed that peramivir was generally well-tolerated. These data will be submitted for presentation at an upcoming medical conference. Based on the study's preliminary results, Shionogi has commenced preparations for a Phase III trial of i.v. peramivir in the outpatient setting.

The Phase II study was a randomized, double-blind, placebo-controlled trial, which enrolled 300 subjects who had a positive rapid antigen test indicating acute influenza illness. Subjects were randomized to receive an i.v. injection of placebo or one of two doses of peramivir (300 mg and 600 mg) as a single dose administered within 48 hours of symptom onset.

"The Shionogi study supports clinical efficacy for i.v. peramivir in the treatment of seasonal influenza," commented Rich Whitley, M.D., Professor in the Department of Pediatrics at the University of Alabama at Birmingham. "These data allow us to optimistically anticipate the impact peramivir may have as a potential treatment for influenza in this setting. With the advent of influenza virus resistant to currently approved neuraminidase inhibitors, new therapeutic options such a
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
2. BioCryst Updates Peramivir Clinical Development Plan
3. BioCryst Provides Forodesine HCl Update
4. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... When looking at the types of people ... into one of two categories: those that have a weak appetite or those that have ... still want to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... 03, 2015 , ... Each year, the editors of Modern ... activists, corporate executives, entrepreneurs, health care professionals, and others have had the most ... magazine to tap the National League for Nursing’s outspoken CEO, Beverly Malone ...
(Date:9/2/2015)... ... 2015 , ... Healthegy, a leading producer of conferences, podcasts ... deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ) ... Larry Renfro, CEO of Optum, will deliver the morning address. In his post, ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... a colourless, odourless and tasteless chemical element - could ... ,Patients with chronic obstructive pulmonary disease (COPD) have ... the lungs at the end of each breath. This ... reasons for shortness of breath experienced by these patients, ...
... Here’s the good news, the bad news, and some more ... Americans, according to one recent study) are satisfied// with their ... way of having a good sex life, from prescription medication ... ,In many cases, physicians can work with their patients to ...
... Andhra Pradesh and Tamil Nadu will upgrade their existing ... ,"It has been decided to upgrade the hospitals in ... Vice Admiral surgeon Vijay K. Singh, director general of ... ,Singh said a Rs.3-billion budget has been sanctioned, ...
... one in three children in California is overweight or at ... health insurance company.// ,There are even more ... satellite cities. ,The number of overweight children ... rest of California, and nearly doubles the national rate, said ...
... Jammu and Kashmir by humanitarian group Médecins Sans Frontières (MSF) ... and more than one in 10 had been victims of ... ,The report by the Holland-based MSF is based on ... in mid-2005. The survey group defined 1989 as the beginning ...
... have made a Startling discovery. The researchers who want ... their intake of calories is restricted have found that ... on longevity in the fruit flies. ,Scientists ... increase the lifespan of many species, but the mechanism ...
Cached Medicine News:Health News:Helium Helps COPD Sufferers to Exercise 2Health News:Health Issues That Can Impact Sexual Satisfaction 2Health News:Health Issues That Can Impact Sexual Satisfaction 3Health News:Health Issues That Can Impact Sexual Satisfaction 4Health News:South India to Have Modern Military Hospitals 2Health News:Mental Health of Kashmiris Needs Urgent Attention: Survey 2Health News:Food Odors Linked With Lifespan in Fruit Flies 2Health News:Food Odors Linked With Lifespan in Fruit Flies 3Health News:Food Odors Linked With Lifespan in Fruit Flies 4Health News:Food Odors Linked With Lifespan in Fruit Flies 5
... With the increase in Endoscopic cases it is ... Monitor with the Surgical Light. This combination ... without having to adopt an uncomfortable pose. ... including the NUVO Monitoring System. As such ...
... This configuration offers all the performance of a ... perfectly for use in Outpatient Settings, Minor Procedure ... Mounting two single lights either side of the ... in a General OR when combining Flat Screen ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
Medicine Products: